Table 3.

Baicalein, baicalin, and wogonin performance on different brain ischemia models.

Models	Species	Baicalein		Baicalin		Wogonin		Reference(s)
		Conc.	Effects	Conc.	Effects	Conc.	Effects
SCEM	Rabbit	100 mg/kg	Improve behavioral performance					[93]
MCAO	Rat/mouse	20 mg/kg; 200 mg/kg	Decrease the infarct volume and neurological score; inhibiting 12/15-LOX-induced oxidative toxicity; regulate M1/M2 transformation of microglia/macrophages and block NF-κB nuclear translocation; suppress PARP-1/AIF pathway-induced neuroinflammation; antioxidant 12/15-LOX inhibitor	5, 100, and 200 mg/kg	Reduced the neurological deficit scores, cerebral infarct volume by inhibiting TLR2/4-mediated NF-κB pathway, and expression of iNOS, COX2, and caspase3	20 mg/kg; 50 μM	Reduce infarct area and improve behavior performance through upregulating TGF-β1	[92, 94, 106–109, 112–116, 118, 119]
GCI/R	Gerbil/rats			100 mg/kg; 200 mg/kg	Improve learning and memory ability post-I/R injury via anti-inflammatory and antiapoptosis; perform neuroprotection by upregulating HSP70 expression and influencing MAPK cascades in the gerbil hippocampus	0.5, 1, and 10 mg/kg	Increase neuron survival in the hippocampus area by suppressing inflammation (iNOS, TNF-α)	[100, 101, 103, 117, 118]